Clinical trial DaNIS-2
A randomized, double-blind, phase III study, comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
| Cancers | |
|---|---|
| Organ | pancreas |
| Trial status | Trial closed for recruitment |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Novartis |
| EudraCT Identifier | 2021-000591-10 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04935359 |
| Last update |